FMR LLC lessened its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 6.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 128,972,819 shares of the company's stock after selling 8,942,674 shares during the period. FMR LLC owned approximately 6.73% of Kenvue worth $2,753,570,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of KVUE. Federated Hermes Inc. increased its holdings in shares of Kenvue by 11.6% in the 4th quarter. Federated Hermes Inc. now owns 8,420,638 shares of the company's stock worth $179,781,000 after buying an additional 876,624 shares during the last quarter. Waterloo Capital L.P. bought a new stake in Kenvue during the fourth quarter worth approximately $288,000. Envestnet Asset Management Inc. raised its position in Kenvue by 79.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 10,224,056 shares of the company's stock valued at $218,284,000 after purchasing an additional 4,523,918 shares during the period. Aviva PLC lifted its stake in shares of Kenvue by 1,159.8% in the 4th quarter. Aviva PLC now owns 1,154,701 shares of the company's stock valued at $24,653,000 after purchasing an additional 1,063,043 shares during the last quarter. Finally, Resona Asset Management Co. Ltd. purchased a new position in shares of Kenvue in the 4th quarter worth approximately $13,601,000. Hedge funds and other institutional investors own 97.64% of the company's stock.
Kenvue Stock Up 1.3 %
Shares of KVUE stock traded up $0.28 during mid-day trading on Friday, hitting $22.15. The stock had a trading volume of 4,119,405 shares, compared to its average volume of 16,887,110. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm's 50-day moving average is $22.62 and its two-hundred day moving average is $22.41. The firm has a market capitalization of $42.33 billion, a P/E ratio of 41.63, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.70%. The ex-dividend date was Wednesday, February 12th. Kenvue's payout ratio is 154.72%.
Analyst Ratings Changes
A number of brokerages recently issued reports on KVUE. Evercore ISI assumed coverage on Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price target for the company. Redburn Atlantic began coverage on shares of Kenvue in a research note on Thursday. They set a "neutral" rating and a $23.50 price target for the company. Barclays upped their price target on shares of Kenvue from $21.00 to $23.00 and gave the company an "equal weight" rating in a report on Thursday, March 27th. Royal Bank of Canada restated a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft downgraded Kenvue from a "buy" rating to a "hold" rating and reduced their price target for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $23.96.
View Our Latest Stock Analysis on KVUE
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Recommended Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
